12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Company News  |  Deals

ProBioGen, Boehringer Ingelheim deal

Boehringer received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC) activity of antibodies....

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >